Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Drug Resistance in Non-Hodgkin Lymphomas
Pavel Klener, Magdalena Klánová
International Journal of Molecular Sciences (2020) Vol. 21, Iss. 6, pp. 2081-2081
Open Access | Times Cited: 56

Showing 1-25 of 56 citing articles:

Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Laurie H. Sehn, Alex F. Herrera, Christopher R. Flowers, et al.
Journal of Clinical Oncology (2019) Vol. 38, Iss. 2, pp. 155-165
Open Access | Times Cited: 633
Drug-Resistance Mechanism and New Targeted Drugs and Treatments of Relapse and Refractory DLBCL
Jing Zhang, Yan Gu, Baoan Chen
Cancer Management and Research (2023) Vol. Volume 15, pp. 245-255
Open Access | Times Cited: 24
Carbonic Anhydrase IX Inhibitors as Candidates for Combination Therapy of Solid Tumors
Stanislav Kalinin, Anna Malkova, Tatiana V. Sharonova, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 24, pp. 13405-13405
Open Access | Times Cited: 47
Innovations in Antibody-Drug Conjugate (ADC) in the Treatment of Lymphoma
Ali Al Sbihi, Maryam Alasfour, Georgios Pongas
Cancers (2024) Vol. 16, Iss. 4, pp. 827-827
Open Access | Times Cited: 7
Drug resistance in human cancers — Mechanisms and implications
Sudikshaa Vijayakumar, Raveena Dhakshanamoorthy, Akshaya Baskaran, et al.
Life Sciences (2024) Vol. 352, pp. 122907-122907
Closed Access | Times Cited: 5
miRNA-Based Therapies in B Cell Non-Hodgkin Lymphoma
Teresa Fuertes, Almudena R. Ramiro, Virginia G. de Yébenes
Trends in Immunology (2020) Vol. 41, Iss. 10, pp. 932-947
Open Access | Times Cited: 39
Drug Resistance in Hematological Malignancies
Patrick Auberger, Jérôme Tamburini‐Bonnefoy, Alexandre Puissant
International Journal of Molecular Sciences (2020) Vol. 21, Iss. 17, pp. 6091-6091
Open Access | Times Cited: 35
Targeting refractory diffuse large B cell lymphoma by CAR-WEE1 T-cells: In vitro evaluation
Hadeer Mohamed Ahmed, Said S. Moselhy, Magda I. Mohamad, et al.
Annals of Hematology (2025)
Open Access
Insights into the Molecular Mechanisms and Nanoparticle-Based Therapies for Gastric Cancer: A review
Smarika Chauhan, Eswar Marcharla, Sneha Hariharan, et al.
Results in Engineering (2025), pp. 104238-104238
Open Access
Exploration of Euscaphic Acid on Non-Hodgkin Lymphoma Based on Network Pharmacology, Molecular Docking and Cell Experiment
Guangru Li, Ruiting Wen, Yan Liu, et al.
Natural Product Communications (2025) Vol. 20, Iss. 3
Open Access
As the world turns, evolving lymphoma classifications–past, present and future
Steven H. Swerdlow, James R. Cook
Human Pathology (2019) Vol. 95, pp. 55-77
Closed Access | Times Cited: 29
Specific Cytotoxic Effect of an Auristatin Nanoconjugate Towards CXCR4+ Diffuse Large B-Cell Lymphoma Cells
Aïda Falgàs, Víctor Pallarès, Ugutz Unzueta, et al.
International Journal of Nanomedicine (2021) Vol. Volume 16, pp. 1869-1888
Open Access | Times Cited: 20
Baseline and interim 18F-FDG PET/CT metabolic parameters predict the efficacy and survival in patients with diffuse large B-cell lymphoma
Chengcheng Liao, Qifeng Deng, Lin Zeng, et al.
Frontiers in Oncology (2024) Vol. 14
Open Access | Times Cited: 2
Secondary Resistant Mutations to Small Molecule Inhibitors in Cancer Cells
Abdulaziz Hamid, Ruben C. Petreaca
Cancers (2020) Vol. 12, Iss. 4, pp. 927-927
Open Access | Times Cited: 17
In Vitro Tumor Cell Growth Inhibition Induced by Lophocereus marginatus (DC.) S. Arias and Terrazas Endophytic Fungi Extracts
Jesica María Ramírez-Villalobos, César I. Romo-Sáenz, Karla Morán-Santibañez, et al.
International Journal of Environmental Research and Public Health (2021) Vol. 18, Iss. 18, pp. 9917-9917
Open Access | Times Cited: 15
The inositol 5-phosphatase INPP5B regulates B cell receptor clustering and signaling
Alaa Droubi, Connor Wallis, Karen E. Anderson, et al.
The Journal of Cell Biology (2022) Vol. 221, Iss. 9
Open Access | Times Cited: 11
Liposomal doxorubicin supercharge‐containing front‐line treatment in patients with advanced‐stage diffuse large B‐cell lymphoma or classical Hodgkin lymphoma: Preliminary results of a single‐centre phase II study
Marco Picardi, Claudia Giordano, Novella Pugliese, et al.
British Journal of Haematology (2022) Vol. 198, Iss. 5, pp. 847-860
Open Access | Times Cited: 10
Long non-coding RNA SNHG17 may function as a competitive endogenous RNA in diffuse large B-cell lymphoma progression by sponging miR-34a-5p
Shengjuan Lu, Lin Zeng, Guojun Mo, et al.
PLoS ONE (2023) Vol. 18, Iss. 11, pp. e0294729-e0294729
Open Access | Times Cited: 5
ceRNA Network of lncRNA/miRNA as Circulating Prognostic Biomarkers in Non-Hodgkin Lymphomas: Bioinformatic Analysis and Assessment of Their Prognostic Value in an NHL Cohort
Mara Fernandes, Herlander Marques, Ana Luísa Teixeira, et al.
International Journal of Molecular Sciences (2021) Vol. 23, Iss. 1, pp. 201-201
Open Access | Times Cited: 12
Sex- and Female Age-Dependent Differences in Gene Expression in Diffuse Large B-Cell Lymphoma—Possible Estrogen Effects
Dan Huang, Mattias Berglund, Anastasios Damdimopoulos, et al.
Cancers (2023) Vol. 15, Iss. 4, pp. 1298-1298
Open Access | Times Cited: 4
B‐Cell Chronic Lymphocytic Leukemia and B‐Cell Lymphomas: The Key Role of Micro and Long Noncoding RNAs
Mozhdeh Mohammadian, Maryam Salimi, Behrouz Farhadihosseinabadi, et al.
Journal of Clinical Pharmacy and Therapeutics (2024) Vol. 2024, Iss. 1
Open Access | Times Cited: 1
Clonal hematopoiesis of indeterminate potential (CHIP): A potential contributor to lymphoma
QingQing Luo, Lili Zhou, Dong-feng Luo, et al.
Critical Reviews in Oncology/Hematology (2024) Vol. 206, pp. 104589-104589
Closed Access | Times Cited: 1
The Natural Estrogen Receptor Beta Agonist Silibinin as a Promising Therapeutic Tool in Diffuse Large B-cell Lymphoma
Elena Ortona, Silvia L. Locatelli, Maria Pagano, et al.
Anticancer Research (2022) Vol. 42, Iss. 2, pp. 767-779
Open Access | Times Cited: 7
Theranostic Potentials of Gold Nanomaterials in Hematological Malignancies
Md Salman Shakil, Mahruba Sultana Niloy, Kazi Mustafa Mahmud, et al.
Cancers (2022) Vol. 14, Iss. 13, pp. 3047-3047
Open Access | Times Cited: 7
Scaffold-mediated switching of lymphoma metabolism in culture
Rachana Bhatt, Dashnamoorthy Ravi, Andrew M. Evens, et al.
Cancer & Metabolism (2022) Vol. 10, Iss. 1
Open Access | Times Cited: 7
Page 1 - Next Page

Scroll to top